Key clinical point : Teriparatide may have better therapeutic effects than denosumab in glucocorticoid-induced osteoporosis (GIO) patients previously treated with bisphosphonates.
Major finding : Teriparatide group showed a significantly greater improvement in the bone mineral density (BMD) of lumbar spine ( P less than .01) and femoral neck ( P less than .05) vs. denosumab group at 12 months, but not at 24 months. At 24 months, BMD of lumbar spine had significantly increased from baseline in both the groups, whereas BMD of femoral neck had increased only in the teriparatide group.
Study details : A prospective, open-label, nonrandomized, single-center study including 47 patients with GIO assigned to either teriparatide group (n = 23) or denosumab group (n = 24).
Disclosures: The study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Hirooka Y et al. Bone Rep. 2020 Jul 4. doi: 10.1016/j.bonr.2020.100293 .